echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Clin Gastroenterology H: The level of tumor necrosis factor produced by blood monocytes can be used to predict the response of patients with inflammatory bowel disease to infliximab

    Clin Gastroenterology H: The level of tumor necrosis factor produced by blood monocytes can be used to predict the response of patients with inflammatory bowel disease to infliximab

    • Last Update: 2021-04-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    The emergence of anti-tumor necrosis factor (TNF) drugs has completely changed the treatment mode of patients with inflammatory bowel disease (IBD).


     

     


    medsci.


     

     


    In patients with Crohn's disease, this cut-off value (500 pg/ml TNF) identifies responders with 100% sensitivity and 82% specificity.


     

     

    This study found that PBMC (especially CD14 + cells) of patients with IBD produce high levels of TNF, which can identify patients who are most likely to have a clinical response to infliximab treatment.


    This study found that the PBMC (especially CD14 + cells) of patients with IBD produce high levels of TNF, which can identify patients who are most likely to have a clinical response to infliximab treatment.


     

     

    Original source:

    Bosse Jessen.


    Level of Tumor Necrosis Factor Production by Stimulated Blood Mononuclear Cells Can Be Used to Predict Response of Patients With Inflammatory Bowel Diseases to Infliximab.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.